Table 3.

SNPs in SOD2, CAT, GPX1, and GPX4 and risk of lethal prostate cancer among men initially diagnosed with nonmetastatic prostate cancer in the PHS and the HPFS

Genotype frequenciesCodominant modelaAdditive modela
SNPDeaths/metastases n (%)All other cases n (%)HR (95% CI)HR (95% CI)P value
SOD2
 –rs4880b0.89 (0.73–1.08)0.23
 —TT58 (28)507 (24)1.0 (ref.)
 —CT104 (50)1,031 (50)0.89 (0.65–1.23)
 —CC45 (22)539 (26)0.79 (0.53–1.16)
 –rs7855c0.70 (0.42–1.17)0.17
 —TT192 (92)1,886 (90)1.0 (ref.)
 —CT16 (8)209 (10)0.70 (0.42–1.17)
 —CC0 (0)5 (0)
 –rs28429801.05 (0.83–1.33)0.67
 —AA127 (62)1,310 (63)1.0 (ref.)
 —AT68 (33)660 (32)1.02 (0.76–1.37)
 —TT11 (5)98 (5)1.18 (0.64–2.19)
 –rs5746151c0.76 (0.48–1.21)0.25
 —GG182 (90)1,830 (88)1.0 (ref.)
 —AG20 (10)247 (12)0.76 (0.48–1.21)
 —AA0 (0)8 (0)
 –rs69175891.22 (0.97–1.52)0.09
 —AA103 (53)1,255 (61)1.0 (ref.)
 —AG80 (41)693 (34)1.37 (1.02–1.83)
 —GG11 (6)109 (5)1.17 (0.63–2.19)
CAT
 –rs5118950.88 (0.72–1.08)0.23
 —CC81 (40)728 (35)1.0 (ref.)
 —CT90 (45)997 (48)0.82 (0.61–1.11)
 —TT31 (15)333 (16)0.82 (0.54–1.24)
 –rs7692171.08 (0.86–1.36)0.52
 —CC126 (61)1,263 (60)1.0 (ref.)
 —CT68 (33)733 (35)0.97 (0.72–1.31)
 —TT14 (7)94 (5)1.43 (0.82–2.48)
 –rs10011790.97 (0.77–1.21)0.76
 —CC119 (59)1,222 (59)1.0 (ref.)
 —CT76 (37)727 (35)1.10 (0.83–1.47)
 —TT8 (4)117 (6)0.66 (0.32–1.35)
 –rs2076556c1.08 (0.79–1.48)0.64
 —AA155 (75)1,566 (76)1.0 (ref.)
 —AG49 (24)469 (23)1.08 (0.79–1.48)
 —GG2 (1)25 (1)
 –rs110327001.08 (0.88–1.32)0.48
 —AA87 (44)940 (46)1.0 (ref.)
 —AC88 (44)882 (43)1.11 (0.82–1.49)
 —CC24 (12)229 (11)1.13 (0.72–1.78)
 –rs11032703c0.88 (0.63–1.24)0.47
 —CC164 (80)1,615 (78)1.0 (ref.)
 —CT36 (18)415 (20)0.88 (0.63–1.24)
 —TT5 (2)35 (2)
GPX1
 –rs34481.10 (0.89–1.37)0.39
 —GG115 (56)1,178 (57)1.0 (ref.)
 —GA76 (37)748 (36)1.08 (0.81–1.44)
 —AA15 (7)126 (6)1.26 (0.74–2.16)
 –rs18006680.97 (0.79–1.19)0.74
 —CC90 (45)933 (45)1.0 (ref.)
 —CT89 (44)893 (43)0.98 (0.73–1.31)
 —TT23 (11)244 (12)0.92 (0.58–1.46)
GPX4
 –rs20744521.06 (0.85–1.31)0.63
 —CC105 (52)1,169 (57)1.0 (ref.)
 —CT86 (43)759 (37)1.22 (0.92–1.63)
 —TT11 (5)140 (7)0.83 (0.45–1.54)
 –rs37461650.83 (0.68–1.01)0.06
 —AA56 (28)549 (27)1.0 (ref.)
 —AG110 (55)990 (49)1.06 (0.77–1.46)
 —GG35 (17)501 (25)0.65 (0.43–0.99)
 –rs42396050.85 (0.69–1.05)0.14
 —AA52 (30)498 (26)1.0 (ref.)
 —AG93 (53)1,006 (52)0.92 (0.65–1.29)
 —GG31 (18)443 (23)0.71 (0.45–1.10)
  • aAdjusted for age at diagnosis (years).

  • bC = alanine (A) and T = valine (V).

  • cThe heterozygous and homozygous less common allele categories were combined when <5% of the study population was homozygous for the less common allele.